The Corporation’s equity compensation plans include the 2003 Stock Incentive Plan, the 2013 Stock Option and Incentive Plan and the 2022 Long Term Incentive Plan, which have been approved by the Corporation’s Board of Directors and shareholders. Following shareholder approval of the 2022 Long Term Incentive Plan on April 26, 2022, awards are being granted only from the 2022 Long Term Incentive Plan.

The maximum number of shares of common stock that may be issued under the 2022 Long Term Incentive Plan is 600,000 and is subject to adjustment in accordance with the terms of this plan. The types of permitted equity awards under the 2022 Long Term Incentive Plan include stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights.

As of December 31, 2022, a total of 1,438,109 common stock shares were reserved for issuance under the 2003 Stock Incentive Plan, 2013 Stock Option and Incentive Plan and 2022 Long Term Incentive Plan.

The following table presents share-based compensation expense and the related income tax benefits recognized in the Consolidated Statements of Income for stock options, restricted stock units and performance share units:


(Dollars in thousands)
Years ended December 31,	2022	2021	2020
Share-based compensation expense	$3,247	$3,316	$3,766
Related income tax benefits (1)	$857	$978	$801

(1)Includes $78 thousand and $182 thousand, respectively, of excess tax benefits recognized upon the settlement of share-based compensation awards in 2022 and 2021. Includes $103 thousand of excess tax expenses recognized upon the settlement of share-based compensation awards in 2020.

As of December 31, 2022, there was $5.1 million of total unrecognized compensation cost related to share-based compensation arrangements, including stock options, restricted stock units and performance share units granted under the Plans. That cost is expected to be recognized over a weighted average period of 1.9 years.

The exercise price of each stock option may not be less than the fair market value of the Bancorp’s common stock on the date of grant, and options shall have a term of no more than ten years. Stock options are designated as either non-qualified or incentive stock options. For the years ended 2022, 2021 and 2020, all stock options granted by the Corporation were designated as non-qualified stock options.

Washington Trust uses historical data to estimate stock option exercise and employee departure behavior in the option-pricing model. The expected term of options granted was derived from the output of the option valuation model and represents the period of time that options granted are expected to be outstanding. Expected volatility was based on historical volatility of Washington Trust shares. The risk-free rate for periods within the contractual life of the stock option was based on the U.S. Treasury yield curve in effect at the date of grant.

The following presents the assumptions used in determining the grant date fair value of the stock option awards granted to certain key employees:


	2022		2021		2020
Options granted	57,700		53,700		81,530
Cliff vesting period (years)	3		3		3
Expected term (years)	6.5		6.5		6.5
Expected dividend yield	3.90	%	3.80	%	3.69	%
Weighted average expected volatility	31.67	%	31.50	%	29.89	%
Weighted average risk-free interest rate	4.15	%	1.41	%	0.46	%
Weighted average grant-date fair value	$12.01		$11.10		$5.75

The following table presents a summary of stock options outstanding as of and for the year ended December 31, 2022:


	Number of Stock Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (000’s)
Beginning of period	322,140	$45.95
Granted	57,700	48.50
Exercised	(7,950)	30.67
Forfeited or expired	—	—
End of period	371,890	$46.67	6.95	$1,514
Options exercisable at end of period	186,640	$49.54	5.20	$410

The total intrinsic value is the amount by which the fair value of the underlying stock exceeds the exercise price of an option on the exercise date.

The following table presents additional information concerning options outstanding and options exercisable at December 31, 2022:


	Options Outstanding			Options Exercisable
Exercise Price Ranges	Number of Shares	Weighted Average Remaining Life (Years)	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price


$30.01 to $40.00	98,998	6.32	33.17	25,148	35.92
$40.01 to $50.00	135,006	7.68	47.45	77,306	46.67
$50.01 to $60.00	137,886	6.69	55.60	84,186	56.24




Total	371,890	6.95	$46.67	186,640	$49.54

The total intrinsic value of stock options exercised during the years ended December 31, 2022, 2021 and 2020 was $142 thousand, $897 thousand and $46 thousand, respectively.

In 2022, 2021 and 2020, the Corporation granted to directors and certain key employees 21,467, 19,185 and 27,385 restricted stock units, respectively, with 3-year cliff vesting.

The following table presents a summary of restricted stock units as of and for the year ended December 31, 2022:


	Number of Shares	Weighted Average Grant Date Fair Value
Beginning of period	66,285	$45.41
Granted	21,467	50.03
Vested	(22,416)	49.52
Forfeited	(24)	52.18
End of period	65,312	$45.51

The Corporation granted performance share units to certain key employees providing the opportunity to earn shares of common stock over a 3-year to 5-year performance period. The number of shares to be vested will be contingent upon the Corporation’s attainment of certain performance measures as detailed in the performance share unit award agreements.


		Grant Date Fair Value per Share	Weighted Average Current Performance Assumption	Expected Number of Shares
Performance share units awarded in:	2022	$59.31	130%	39,676
	2021	46.15	120%	43,848
	2020	34.22	120%	56,256

	2018	54.25	124%	5,158
Total				144,938

The following table presents a summary of performance share units as of and for the year ended December 31, 2022:


	Number of Shares	Weighted Average Grant Date Fair Value
Beginning of period	159,572	$43.09
Granted (1)	21,379	59.31
Vested	(34,573)	52.87
Forfeited	(1,440)	52.18
End of period	144,938	$45.41

(1)The number of shares include adjustments made to performance measure estimates on outstanding awards that have not yet vested. The weighted average grant date fair value pertains only to awards granted during the year.